Kelly Chien
0000-0001-6024-1613
9 papers found
Refreshing results…
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome
Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
Differential Prognostic Impact of RUNX1 Mutations According to Frontline Therapy in Patients with Acute Myeloid Leukemia
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Missing publications? Search for publications with a matching author name.